Table 2.
Cox regression model for the factors associated with various clinical outcomes in patients with complete data for at least 1 of the serum fibrosis formulae.
| Parameters | Chronic hepatitis B |
Chronic hepatitis C |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariable |
Univariate |
Multivariable |
|||||||||
| HR | 95% CI | p value | aHR | 95% CI | p value | HR | 95% CI | p value | aHR | 95% CI | p value | |
|
HCC | ||||||||||||
| Male sex | 2.68 | (2.49–2.89) | <0.001 | 2.23 | (1.98–2.50) | <0.001 | 0.98 | (0.82–1.17) | 0.819 | 1.70 | (1.54–1.87) | <0.001 |
| Age (years) | 1.02 | (1.01–1.02) | <0.001 | 1.02 | (1.02–1.03) | <0.001 | 1.03 | (1.03–1.04) | <0.001 | 1.04 | (1.04–1.05) | <0.001 |
| Albumin (g/L) | 0.95 | (0.95–0.96) | <0.001 | 0.98 | (0.97–0.98) | <0.001 | 0.99 | (0.98–1.00) | 0.117 | 0.95 | (0.95–0.96) | <0.001 |
| ALT (>ULN) | 2.59 | (2.44–2.75) | <0.001 | 1.77 | (1.61–1.94) | <0.001 | 2.83 | (2.37–3.38) | <0.001 | 0.89 | (0.82–0.98) | 0.015 |
| Positive HBeAg | 1.42 | (1.28–1.57) | <0.001 | 1.46 | (1.31–1.62) | <0.001 | – | – | – | – | – | – |
| Antiviral treatment | 1.79 | (1.69–1.90) | <0.001 | 1.68 | (1.53–1.84) | <0.001 | 0.05 | (0.01–0.18) | <0.001 | 1.79 | (1.51–2.11) | <0.001 |
| Advanced liver fibrosis |
3.22 |
(3.02–3.42) |
<0.001 |
1.41 |
(1.25–1.58) |
<0.001 |
2.90 |
(2.45–3.43) |
<0.001 |
1.34 |
(1.19–1.50) |
<0.001 |
|
Hepatic events (non-HCC) | ||||||||||||
| Male sex | 1.57 | (1.48–1.67) | <0.001 | 1.32 | (1.20–1.46) | <0.001 | 0.76 | (0.66–0.87) | <0.001 | 0.87 | (0.76–1.01) | 0.067 |
| Age (years) | 1.02 | (1.02–1.02) | <0.001 | 1.01 | (1.01–1.02) | <0.001 | 1.02 | (1.01–1.02) | <0.001 | 1.00 | (1.00–1.01) | 0.066 |
| Albumin (g/L) | 0.92 | (0.92–0.92) | <0.001 | 0.95 | (0.94–0.95) | <0.001 | 0.95 | (0.94–0.96) | <0.001 | 0.96 | (0.95–0.97) | <0.001 |
| ALT (>ULN) | 1.94 | (1.83–2.04) | <0.001 | 1.28 | (1.18–1.40) | <0.001 | 2.12 | (1.85–2.44) | <0.001 | 1.50 | (1.30–1.74) | <0.001 |
| Positive HBeAg | 1.17 | (1.06–1.29) | 0.002 | 1.17 | (1.06–1.30) | 0.002 | – | – | – | – | – | – |
| Antiviral treatment | 1.18 | (1.11–1.25) | <0.001 | 1.01 | (0.93–1.11) | 0.758 | 0.04 | (0.01–0.13) | <0.001 | 0.06 | (0.02–0.19) | <0.001 |
| Advanced liver fibrosis |
4.34 |
(4.10–4.59) |
<0.001 |
1.25 |
(1.13–1.40) |
<0.001 |
4.01 |
(3.51–4.59) |
<0.001 |
1.56 |
(1.32–1.85) |
<0.001 |
|
Death | ||||||||||||
| Male sex | 1.47 | (1.42–1.53) | <0.001 | 1.54 | (1.43–1.66) | <0.001 | 1.22 | (1.11–1.33) | <0.001 | 1.70 | (1.54–1.87) | <0.001 |
| Age (years) | 1.05 | (1.05–1.05) | <0.001 | 1.04 | (1.04–1.04) | <0.001 | 1.04 | (1.04–1.05) | <0.001 | 1.04 | (1.04–1.05) | <0.001 |
| Albumin (g/L) | 0.91 | (0.91–0.91) | <0.001 | 0.93 | (0.93–0.94) | <0.001 | 0.94 | (0.94–0.95) | <0.001 | 0.95 | (0.95–0.96) | <0.001 |
| ALT (>ULN) | 1.01 | (0.97–1.05) | 0.693 | 0.93 | (0.87–1.00) | 0.037 | 0.90 | (0.82–0.97) | 0.011 | 0.89 | (0.82–0.98) | 0.015 |
| Positive HBeAg | 0.76 | (0.70–0.83) | <0.001 | 0.92 | (0.85–1.01) | 0.069 | – | – | – | – | – | – |
| Antiviral treatment | 3.00 | (2.89–3.12) | <0.001 | 2.32 | (2.17–2.48) | <0.001 | 1.22 | (1.04–1.43) | 0.017 | 1.79 | (1.51–2.11) | <0.001 |
| Advanced liver fibrosis | 2.45 | (2.35–2.56) | <0.001 | 1.41 | (1.29–1.53) | <0.001 | 1.80 | (1.63–1.98) | <0.001 | 1.34 | (1.19–1.50) | <0.001 |
aHR, adjusted hazard ratio; ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; HR, hazard ratio; ULN, upper limit of normal.